The charing cross hospital experience with temozolomide in patients with gliomas
- 31 December 1996
- journal article
- clinical trial
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 32 (13), 2236-2241
- https://doi.org/10.1016/s0959-8049(96)00258-4
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- A Registration and Interpolation Procedure for Subvoxel Matching of Serially Acquired MR ImagesJournal of Computer Assisted Tomography, 1995
- Survival in patients with recurrent glioma as a measure of treatment efficacy: Prognostic factors following nitrosourea chemotherapyEuropean Journal Of Cancer, 1994
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumoursEuropean Journal Of Cancer, 1993
- Enhancement of Nitrosourea Activity in Medulloblastoma and Glioblastoma MultiformeJNCI Journal of the National Cancer Institute, 1992
- A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4Cancer, 1991
- Prognostic factors for high-grade malignant glioma: Development of a prognostic indexJournal of Neuro-Oncology, 1990
- The role of chemotherapy in the treatment of gliomas in adultsCancer Treatment Reviews, 1989
- A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma: Report to the Medical Research Council by the Brain Tumor Working PartyInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Correlation between O6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N′-nitro-N-nitrosoguanidineCarcinogenesis: Integrative Cancer Research, 1984
- Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomasJournal of Neurosurgery, 1978